A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
660
Number of Participants With Deaths, Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and moderate or severe AEs
To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with deaths, SAEs, AEs leading to discontinuation, and moderate and severe AEs.
Time frame: Up to 104 weeks
Number of Subjects with Clinically Significant Laboratory Abnormalities
To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with grade 3 or 4 laboratory abnormalities.
Time frame: Up to 104 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Accel Research
Birmingham, Alabama, United States
Onyx Clinical Trials
Peoria, Arizona, United States
Xenoscience, Inc.
Phoenix, Arizona, United States
University of Arizona / Banner University Medical Center Phoenix
Phoenix, Arizona, United States
Barrow Neurological Institute
Phoenix, Arizona, United States
ARENSIA Exploratory Medicine
Phoenix, Arizona, United States
Center for Neurosciences
Tucson, Arizona, United States
Clinical Trials, Inc.
Little Rock, Arkansas, United States
WRN
Rogers, Arkansas, United States
University of California San Diego
La Jolla, California, United States
...and 271 more locations